As lack of BCL6 in activated CD8 T cells stimulated the GLUT3-mediated glycolysis pathway, ultimately retarding CD8+ T-cell exhaustion and enhancing their effector functions, we surmise that this mechanism explains the T-cell dependence of Fx1 drug-induced tumor resistance. Here, BCL6 is linked to neoplasm.